Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 4.8 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 250 microgram); estradiol, quantity: 0.512 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polyethylene terephthalate; ethylene/vinyl acetate copolymer; polyvinylidene flouride; ethyl acetate; ethanol; toluene; acrylates/va copolymer; polytrimethylhydrosilylsiloxane; xylene; ammonia; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 2.7 mg (equivalent: estradiol, qty 50 microgram; equivalent: norethisterone acetate, qty 140 microgram); estradiol, quantity: 0.62 mg (equivalent: estradiol, qty 50 microgram) - drug delivery system, transdermal - excipient ingredients: oleic acid; dipropylene glycol; povidone; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; ethanol; acrylates/va copolymer; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. for prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estalis continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Kanada - angličtina - Health Canada

biologische heilmittel heel gmbh - melissa officinalis - liquid - 10d - melissa officinalis 10d - homeopathic products

Kanada - angličtina - Health Canada

biologische heilmittel heel gmbh - melissa officinalis - liquid - 4d - melissa officinalis 4d - homeopathic products

Kanada - angličtina - Health Canada

dolisos laboratoires s.a. - melissa officinalis - drops - 1dh - melissa officinalis 1dh - homeopathic products

Kanada - angličtina - Health Canada

weleda ag heilmittelbetriebe - melissa officinalis - drops - 2d - melissa officinalis 2d - homeopathic products

Kanada - angličtina - Health Canada

dolisos canada inc. - melissa officinalis - globules - 1x - melissa officinalis 1x - homeopathic products

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 16.8mg;   - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 2.1mg;   - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 4.2mg;   - transdermal patch - 25 mcg/h - active: fentanyl 4.2mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.